MX385207B - Aglutinantes de tnf mejorados. - Google Patents

Aglutinantes de tnf mejorados.

Info

Publication number
MX385207B
MX385207B MX2018005992A MX2018005992A MX385207B MX 385207 B MX385207 B MX 385207B MX 2018005992 A MX2018005992 A MX 2018005992A MX 2018005992 A MX2018005992 A MX 2018005992A MX 385207 B MX385207 B MX 385207B
Authority
MX
Mexico
Prior art keywords
tnf
isvds
compounds
necrosis factor
tumor necrosis
Prior art date
Application number
MX2018005992A
Other languages
English (en)
Spanish (es)
Other versions
MX2018005992A (es
Inventor
Heeke Gino Van
Joachim Boucneau
Marie-Ange Buyse
Peter Casteels
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2018005992A publication Critical patent/MX2018005992A/es
Publication of MX385207B publication Critical patent/MX385207B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Insulating Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
MX2018005992A 2015-11-12 2016-11-14 Aglutinantes de tnf mejorados. MX385207B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562254375P 2015-11-12 2015-11-12
PCT/EP2016/077595 WO2017081320A1 (en) 2015-11-12 2016-11-14 Improved tnf binders

Publications (2)

Publication Number Publication Date
MX2018005992A MX2018005992A (es) 2019-01-31
MX385207B true MX385207B (es) 2025-03-04

Family

ID=57348648

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005992A MX385207B (es) 2015-11-12 2016-11-14 Aglutinantes de tnf mejorados.

Country Status (37)

Country Link
US (2) US10544211B2 (cg-RX-API-DMAC7.html)
EP (2) EP3191511B1 (cg-RX-API-DMAC7.html)
JP (2) JP6962915B2 (cg-RX-API-DMAC7.html)
KR (2) KR102641194B1 (cg-RX-API-DMAC7.html)
CN (1) CN108473563B (cg-RX-API-DMAC7.html)
AU (2) AU2016352943B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018009714A8 (cg-RX-API-DMAC7.html)
CA (2) CA3234178A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018001291A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018005915A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180311A (cg-RX-API-DMAC7.html)
CY (1) CY1120303T1 (cg-RX-API-DMAC7.html)
DK (1) DK3191511T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2018000122A (cg-RX-API-DMAC7.html)
EC (1) ECSP18042569A (cg-RX-API-DMAC7.html)
ES (1) ES2662418T3 (cg-RX-API-DMAC7.html)
GT (1) GT201800095A (cg-RX-API-DMAC7.html)
HK (1) HK1248716A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20171949T1 (cg-RX-API-DMAC7.html)
HU (1) HUE035805T2 (cg-RX-API-DMAC7.html)
IL (2) IL310373A (cg-RX-API-DMAC7.html)
LT (1) LT3191511T (cg-RX-API-DMAC7.html)
MA (1) MA41653A (cg-RX-API-DMAC7.html)
MD (1) MD3191511T2 (cg-RX-API-DMAC7.html)
ME (1) ME02954B (cg-RX-API-DMAC7.html)
MX (1) MX385207B (cg-RX-API-DMAC7.html)
NO (1) NO2768984T3 (cg-RX-API-DMAC7.html)
PE (1) PE20181317A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018501025A1 (cg-RX-API-DMAC7.html)
PL (1) PL3191511T3 (cg-RX-API-DMAC7.html)
PT (1) PT3191511T (cg-RX-API-DMAC7.html)
RS (1) RS56676B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201803975SA (cg-RX-API-DMAC7.html)
SI (1) SI3191511T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700590T1 (cg-RX-API-DMAC7.html)
TN (1) TN2018000159A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017081320A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SG194982A1 (en) 2011-06-23 2013-12-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
NO2768984T3 (cg-RX-API-DMAC7.html) * 2015-11-12 2018-06-09
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
WO2021110817A1 (en) 2019-12-06 2021-06-10 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
PH12022551214A1 (en) * 2019-12-06 2023-10-09 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting tnf# and il-23
CN112300289B (zh) * 2019-12-30 2022-06-10 中国药科大学 RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
WO2022129572A1 (en) 2020-12-18 2022-06-23 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
JP2024543134A (ja) * 2021-11-29 2024-11-19 江蘇恒瑞医薬股▲ふん▼有限公司 修飾されたタンパク質又はポリペプチド
EP4611728A1 (en) * 2022-11-04 2025-09-10 St. Jude Children's Research Hospital, Inc. Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
TW202440614A (zh) 2022-12-23 2024-10-16 比利時商艾伯霖克斯公司 基於蛋白質的接合載體
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CN1203178C (zh) 1997-10-27 2005-05-25 尤尼利弗公司 多价抗原结合蛋白
EP1469883A2 (en) 1998-02-19 2004-10-27 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2512545C (en) 2003-01-10 2015-06-30 Karen Silence Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf)
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
DE60334645D1 (de) 2003-11-07 2010-12-02 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
MX2007006593A (es) 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
CN103254309B (zh) * 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
RU2433139C2 (ru) 2005-05-20 2011-11-10 Аблинкс Н.В. Nanobodies tm для лечения заболеваний, опосредованных агрегацией
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
AU2006286563B2 (en) 2005-08-30 2012-02-23 Intrexon Actobiotics Nv Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
WO2007063311A2 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
EP1957536A2 (en) 2005-12-01 2008-08-20 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
EP2152747B1 (en) 2007-05-24 2018-01-03 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
BRPI0911984A2 (pt) 2008-05-16 2016-09-20 Ablynx Nv sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos
AU2010215479B2 (en) * 2009-02-19 2015-01-22 Glaxo Group Limited Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists
KR101470690B1 (ko) 2009-04-10 2014-12-10 아블린쓰 엔.브이. Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
JP2012532620A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
JP6181040B2 (ja) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
SG194982A1 (en) 2011-06-23 2013-12-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN106046168A (zh) 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
UA118833C2 (uk) * 2011-08-17 2019-03-25 Ґлаксо Ґруп Лімітед Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
RS63085B1 (sr) * 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
NO2768984T3 (cg-RX-API-DMAC7.html) 2015-11-12 2018-06-09
US10975141B2 (en) * 2016-02-12 2021-04-13 Ablynx N.V. Method for the production of immunoglobulin single variable domains

Also Published As

Publication number Publication date
RS56676B1 (sr) 2018-03-30
HK1248716A1 (en) 2018-10-19
ECSP18042569A (es) 2018-07-31
SMT201700590T1 (it) 2018-01-11
US20170190769A1 (en) 2017-07-06
GT201800095A (es) 2019-08-15
HUE035805T2 (en) 2018-05-28
KR102641194B1 (ko) 2024-02-26
MA41653A (fr) 2018-01-09
KR20180083382A (ko) 2018-07-20
LT3191511T (lt) 2018-01-10
AU2016352943B2 (en) 2022-10-20
CR20180311A (es) 2018-10-18
CA3234178A1 (en) 2017-05-18
AU2023200113A1 (en) 2023-02-16
IL259269A (en) 2018-07-31
IL259269B1 (en) 2024-03-01
DK3191511T3 (en) 2018-01-08
US9745372B2 (en) 2017-08-29
CN108473563A (zh) 2018-08-31
MD3191511T2 (ro) 2018-03-31
PT3191511T (pt) 2017-11-30
CO2018005915A2 (es) 2018-06-20
BR112018009714A8 (pt) 2019-02-26
SI3191511T1 (en) 2018-01-31
EP3266798A3 (en) 2018-03-28
CA3005085C (en) 2024-09-10
US20170267752A1 (en) 2017-09-21
EP3191511A1 (en) 2017-07-19
JP6962915B2 (ja) 2021-11-10
ME02954B (me) 2018-07-20
CY1120303T1 (el) 2019-07-10
RU2018120524A3 (cg-RX-API-DMAC7.html) 2020-09-24
NO2768984T3 (cg-RX-API-DMAC7.html) 2018-06-09
IL259269B2 (en) 2024-07-01
ES2662418T3 (es) 2018-04-06
US10544211B2 (en) 2020-01-28
PH12018501025A1 (en) 2019-01-28
EP3266798A2 (en) 2018-01-10
PL3191511T3 (pl) 2018-03-30
MX2018005992A (es) 2019-01-31
JP7357038B2 (ja) 2023-10-05
JP2019506839A (ja) 2019-03-14
RU2018120524A (ru) 2019-12-13
AU2016352943A1 (en) 2018-06-07
JP2022020666A (ja) 2022-02-01
CL2018001291A1 (es) 2018-09-14
CN108473563B (zh) 2022-06-14
WO2017081320A1 (en) 2017-05-18
BR112018009714A2 (en) 2018-11-21
EP3191511B1 (en) 2017-09-20
PE20181317A1 (es) 2018-08-14
SG11201803975SA (en) 2018-06-28
KR20240029115A (ko) 2024-03-05
HRP20171949T1 (hr) 2018-01-26
TN2018000159A1 (en) 2019-10-04
CA3005085A1 (en) 2017-05-18
DOP2018000122A (es) 2018-09-30
IL310373A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
MX385207B (es) Aglutinantes de tnf mejorados.
MX2023003630A (es) Aglutinantes de albumina de suero mejorados.
MX2023005374A (es) Aglutinantes de albumina serica mejorados.
MX2024008521A (es) Aglutinantes de albumina serica mejorados.
WO2017085172A3 (en) Improved serum albumin binders
EA201891366A1 (ru) Гуманизированные антитела против cd73
MX373485B (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
PH12019500596A1 (en) Recombinant binding proteins and their use
MX2018006072A (es) Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
MX2024005946A (es) Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos.
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
SG10201810507WA (en) Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
MY162737A (en) 4-1bb binding molecules
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
MX2024010472A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
NZ761636A (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
MX371412B (es) ANTICUERPOS BIESPECÍFICOS QUE SE UNEN ESPECÍFICAMENTE A LOXL2 Y ccl.2, COMPOSICIONES DE LOS MISMOS, Y SU USO EN EL TRATAMIENTO DE ESCLERODERMIA.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
HK1258507A1 (zh) 改进的p2x7受体结合剂和包含其的多肽
EA201790437A1 (ru) Антигенсвязывающие белки, связывающиеся с cxcr3